|
|
|
|
|
| Home > |
|
Osteoporosis is often called the "silent disease" because it develops without symptoms. People often don't realize they have it until they break a bone. It's important to find out about the strength of your bones before they break so you can plan ways to decrease bone loss. The best and most common bone density test is a dual energy x-ray absorptiometry, or DEXA, scan of the spine and hip, where fractures are most common and most debilitating. The test is a simple, painless procedure in which a person lies relaxed on a table and an arm of the scanning machine moves above the body. Each scan takes about 5 to 10 minutes. Other tests are also commonly used. Peripheral dual energy absorptiometry, or PDXA, measures bone density in the wrist and forearm. Radiographic absorptiometry, or RA, uses a special hand x-ray to measure bone density of the hand. Quantitative computed tomography, or QCT, usually measures bone density in the spine. This method uses a slightly higher dose of radiation and is often more costly than DEXA. A new testing method, recently approved by the U.S. Food and Drug Administration, is ultrasound testing, which estimates bone strength using sound waves transmitted through the patient's heel for about 10 seconds. Results compare well with bone density measurements by DEXA. The 2008 National Osteoporosis Foundations Guidelines states that postmenopausal women or men over 50 with a T- score of 2.5 or lower at the hip or spine or with a prior hip or spine fracture should be treated. In addition, based on absolute fracture risk calculation, patients with low bone mass (T-score between-1.0 and -2.5 at the femoral neck, total hip or spine) should be treated when there is a 10-year probability of hip fracture that is "3% or a 10-year probability of a major osteoporosis- related fracturet hat is "20% based on the U.S.-adapted WHO algorithm". For More Information from the National Osteoporosis Foundation http://www.nof.org/osteoporosis/bmdtest.htm. As of July 1998, Medicare covers all FDA approved bone density technologies for the following five groups of qualified individuals: estrogen-deficent women at clinical risk for osteoporosis; individuals with vertebral abnormalities; individuals receiving, or planning to receive, long-term glucocorticoid (steriod) therapy; individuals with primary hyperparathyroidism; and individuals being monitored to assess the response or efficacy of an approved osteoporosis drug therapy. Medicare will only reimburse for bone densitometry tests when they are ordered by the treating health care provider. In addition, the frequency of testing is once every two years. If you believe you are among these groups, you may want to ask your doctor about bone density testing. If you are not in these groups, you might still be eligible for testing. Check with your health care provider. It is ideal to get testing done before menopause to assess your bone density prior to bone loss due to a lack of estrogen. Understanding BMD Test Results - click for more info
Screening
Resources International
Society for Clinical Densitometry - http://www.iscd.org/ |
Hosted by the University of Arizona, College of Agriculture and Life Sciences
U
of A Privacy Statement
Copyright © 2006 - 2010 All rights reserved.
Developed by